<DOC>
	<DOCNO>NCT01152645</DOCNO>
	<brief_summary>A phase II open-label study ARQ 197 administer orally twice daily monotherapy patient previously treat advanced/recurrent gastric cancer . The primary endpoint disease control secondary efficacy endpoint include antitumor effect ( tumor response ) , progression-free survival overall survival . The pharmacokinetic profile safety profile also evaluate .</brief_summary>
	<brief_title>Study ARQ 197 Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Japanese Korean voluntary write informed consent study participation A histologically cytologically confirm advanced/recurrent gastric cancer One two prior chemotherapy regimens advanced/recurrent gastric cancer At least one measurable lesion ECOG performance status 0 1 Life expectancy â‰¥3 month Surgery cancer within 4 week prior first dose ARQ 197 Confirmed tumor gastric cancer within 5 year prior first dose ARQ 197 Anticancer chemotherapy , hormone therapy , radiotherapy immunotherapy within 2 week prior first dose ARQ 197 Positive HIV antibody Known symptomatic brain metastasis Gastrointestinal disorder could interfere absorption ARQ 197 operation history gastrointestinal disorder Uncontrolled concomitant disease Patients wish child would agree use contraceptive measure Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced/recurrent gastric cancer</keyword>
</DOC>